Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV-ENOX: Enoxaparin for Thromboembolic Prevention in COVID-19 ICU Patients
NCT04520620Phase 4Withdrawn
- Sponsor
- CHU Saint-Etienne
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by CHU Saint-Etienne. Planned start May 2020; status: withdrawn.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04520620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520620.